Home > Healthcare > Biotechnology > Biotechnology R&D > Isothermal Nucleic Acid Amplification Technology (INAAT) Market

Isothermal Nucleic Acid Amplification Technology (INAAT) Market Trends

Report ID: GMI5251
Published Date: Apr 2022
Report Format: PDF

Download Free Sample

Isothermal Nucleic Acid Amplification Technology Market Trends

The growing incidence of infectious diseases across the globe is anticipated to drive the market expansion considerably throughout the forecast timeframe. Rise in number of infectious diseases such as influenza, HIV, tuberculosis, etc. has increased the demand for better diagnostic and treatment approaches in healthcare facilities.

According to the WHO report 2021, a total of 1.5 million people died in 2020 due to tuberculosis. Globally, tuberculosis is the 13^th leading cause of death and the second leading infectious killer after COVID-19 (above HIV/AIDS). Moreover, in 2020, nearly 10 million people got infected with tuberculosis worldwide. Out of which 5.6 million were men, 3.3 million women and 1.1 million were children. Tuberculosis is present in all countries and age groups.

The conventional option to diagnose such diseases is PCR. However, with advancements in INAAT, the diagnosis can be performed quickly and in cost-effective manner. Thus, the demand of diagnostics for these diseases has surged the need for INAAT solutions. Hence, the increasing prevalence of chronic diseases has stimulated demand for INAAT diagnostic services, thereby fueling overall isothermal nucleic acid amplification technology market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The isothermal nucleic acid amplification technology (INAAT) industry size had crossed USD 1.3 billion in 2021 and is poised to record an 11.8% CAGR between 2022 and 2028 owing to the expanding ageing population and rising technological developments.

The isothermal nucleic acid amplification technology (INAAT) market share from hospitals crossed USD 628 million in 2021 owing to the presence of fully automated instruments to offer quick test results in these facilities as compared to laboratories.

North America held over 43% of the isothermal nucleic acid amplification technology (INAAT) industry share in 2021 owing to the surging preference for these testing techniques over traditional diagnostic procedures in the region.

The INAAT market share from the blood screening application segment is poised to observe a 12% CAGR between 2022 and 2028 due to increasing adoption for understanding the overall blood health, metabolism, liver function, and mineral levels.